Trial Profile
A Phase 2 Trial of Pembrolizumab (MK-3475) in Combination With Platinum Doublet Chemotherapy and Radiotherapy for Participants With Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-799)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms KEYNOTE-799
- Sponsors Merck Sharp & Dohme
- 08 Apr 2024 Status changed from active, no longer recruiting to completed.
- 22 Jun 2023 Planned End Date changed from 15 May 2023 to 12 Mar 2024.
- 07 Jun 2022 Results reporting updated outcomes with 1 year of additional follow-up presented at the 58th Annual Meeting of the American Society of Clinical Oncology